Search clinical trials for: Amcenestrant (SAR439859)

Total 40 results

Sanofi

Completed

Study to Determine Absorption, Metabolism, and Excretion of [14C]-SAR439859, and to Assess Absolute Oral Bioavailability of Amcenestrant (SAR439859), in Healthy Post-menopausal Women

Breast Cancer | Healthy Volunteers

United Kingdom
Sanofi

Active, not recruiting

Evaluation of Orally Administered Amcenestrant (SAR439859) in Japanese Postmenopausal Patients With Advanced Breast Cancer (AMEERA-2) (AMEERA-2)

Breast Cancer

Japan
Sanofi

Terminated

Pharmacokinetics of Amcenestrant in Female Hepatic Impaired Participants as Compared to Participants With Normal Hepatic Function

Hepatic Function Abnormal

Korea, Republic of, Germany
Sanofi

Terminated

Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer (AMEERA-5)

Breast Cancer

United States, Russian Federation, Italy, Australia, Belgium, France, Japan, Ukraine, Netherlands, Argentina, Canada, Portugal, Spain, Austria, Brazil, Bulgaria, Chile, China, Czechia, Finland, Georgia, Germany, Hungary, Korea, Republic... and more
Sanofi

Terminated

Phase 2 Window Study of SAR439859 (Amcenestrant) Versus Letrozole in Post-menopausal Patients With ER+, HER2- Pre-operative Post-menopausal Primary Breast Cancer (AMEERA-4)

Breast Cancer

France, Belgium, United States, Italy, Japan, Puerto Rico, Russian Federation, Spain, Ukraine
Sanofi

Active, not recruiting

Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer (AMEERA-1)

Breast Cancer

Czechia, Belgium, Spain, United States, France, Canada, Italy, Poland, Portugal, United Kingdom
Sanofi

Recruiting

Single Ascending Dose Study of SAR439459 in Adults With Osteogenesis Imperfecta (OI)

Osteogenesis Imperfecta

United States, Australia, Canada, France
Sanofi
European Organisation for Research and Treatment of Cancer - EORTC; Alliance... and other collaborators

Terminated

Study of Amcenestrant (SAR439859) Versus Tamoxifen for Patients With Hormone Receptor-positive (HR+) Early Breast Cancer, Who Have Discontinued Adjuvant Aromatase Inhibitor Therapy Due to Treatment-related Toxicity (AMEERA-6)

Breast Cancer

Chile, China
Daewoong Pharmaceutical Co. LTD.

Recruiting

Study to Evaluate the Efficacy and Safety of FEXUCLUE Tablet

Gastroesophageal Reflux Disease

Korea, Republic of
QuantumLeap Healthcare Collaborative

Recruiting

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (I-SPY)

Breast Cancer | Breast Neoplasms | Breast Tumors | HER2-positive Breast Cancer | Angiosarcoma | Locally Advanced Breast Cancer | HER2-negative Breast Cancer | TNBC - Triple-Negative Breast Cancer | Hormone Receptor Positive Tumor | Hormone Receptor Negative Tumor | Early-stage Breast Cancer

United States
Sanofi

Terminated

A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and Cemiplimab in Patients With Advanced Solid Tumors

Malignant Solid Tumor

France, Spain, Australia, Belgium, Italy, United Kingdom, Taiwan, Estonia, Netherlands, Korea, Republic of, United States, Canada, Germany
M.D. Anderson Cancer Center

Terminated

SAR439459 and Cemiplimab for the Treatment of Advanced or Unresectable Solid Tumors, Strategic Alliance, TACTIC TRIAL

Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
Sanofi

Completed

Sotagliflozin Bioequivalence Study

Type 2 Diabetes Mellitus

United States
Sanofi

Completed

Sotagliflozin Multiple-dose Study in Healthy Chinese Subjects

Diabetes Mellitus

China
Lexicon Pharmaceuticals
Sanofi

Completed

Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus Not Currently Treated With Antidiabetic Therapy

Type 2 Diabetes Mellitus

United States, Canada, Mexico
Lexicon Pharmaceuticals
Sanofi

Terminated

Safety, Tolerability and Pharmacodynamic Activity of Sotagliflozin in Hemodynamically Stable Participants With Worsening Heart Failure

Cardiac Failure Aggravated

United States, Canada, Netherlands
Lexicon Pharmaceuticals
Sanofi

Terminated

Effect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk (SCORED)

Heart Failure | Chronic Kidney Diseases | Type 2 Diabetes Mellitus

Estonia, Belgium, Sweden, Italy, China, United States, Canada, Bulgaria, Chile, Denmark, Hungary, Latvia, Mexico, Russian Federation, Serbia, Spain, Portugal, Romania, Turkey, Poland, Lithuania, Argentina, Australia, Brazil, Czechia, France, Georg... and more
Lexicon Pharmaceuticals
Sanofi

Terminated

Effect of Sotagliflozin on Cardiovascular Events in Participants With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial)

Heart Failure | Type 2 Diabetes Mellitus

Belgium, Canada, Israel, Spain, Germany, Argentina, Chile, Hungary, Korea, Republic of, Latvia, Lithuania, Russian Federation, Sweden, Romania, Poland, Brazil, Denmark, United States, Australia, Austria, Czechia, Finland, France, Greece, Ita... and more
Sanofi

Completed

A Bioequivalence Study Testing Two Formulations of Sotagliflozin in Healthy Male and Female Subjects Under Fasted Conditions

Type 2 Diabetes Mellitus | Healthy Subjects

United States
Sanofi

Completed

Comparison of Sotagliflozin Prototype Tablets With Reference Tablet in Healthy Subjects

Type 2 Diabetes Mellitus | Type 1 Diabetes Mellitus

Germany
Lexicon Pharmaceuticals
Sanofi

Completed

Safety and Efficacy Study of Sotagliflozin on Glucose Control in Participants With Type 2 Diabetes, Moderate Impairment of Kidney Function, and Inadequate Blood Sugar Control (SOTA-CKD3)

Type 2 Diabetes Mellitus | Chronic Kidney Disease Stage 3

United States, Argentina, Brazil, Canada, Colombia, Germany, Hungary, Israel, Italy, Mexico, Poland, Romania, Russian Federation, South Africa, Spain, Ukraine
Sanofi

Completed

A Study to Evaluate the Effect of Food on the Pharmacokinetics of Sotagliflozin and to Explore the Relative Bioavailability in Healthy Subjects

Diabetes Mellitus

United Kingdom
Lexicon Pharmaceuticals
Sanofi

Completed

A Study to Evaluate Safety and Effects of Sotagliflozin 400 and 200 mg on Glucose Control in Participants With Type 2 Diabetes, Severe Impairment of Kidney Function and Inadequate Blood Sugar Control (SOTA-CKD4)

Type 2 Diabetes Mellitus | Chronic Kidney Disease Stage 4

United States, Argentina, Brazil, Colombia, Germany, Hungary, Israel, Italy, Mexico, Poland, Romania, Russian Federation, South Africa, Spain, Ukraine
Lexicon Pharmaceuticals
Sanofi

Completed

Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus on Background of Metformin

Type 2 Diabetes Mellitus

United States, Canada, Hungary, Slovakia
Sanofi

Terminated

Efficacy and Safety of Sotagliflozin Versus Placebo in Chinese Patients With Type 2 Diabetes Mellitus Not Adequately Controlled by Diet and Exercise

Type 2 Diabetes Mellitus

China
Lexicon Pharmaceuticals
Sanofi

Terminated

Efficacy and Bone Safety of Sotagliflozin 400 and 200 mg Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control (SOTA-BONE)

Type 2 Diabetes Mellitus

United States, Australia, Canada, Korea, Republic of, Mexico, New Zealand, Russian Federation, Taiwan
Lexicon Pharmaceuticals
Sanofi

Completed

Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin (SOTA-EMPA)

Type 2 Diabetes Mellitus

United States, Bulgaria, Canada, Czechia, France, Italy, Latvia, Mexico, Russian Federation, Slovakia, Spain, United Kingdom
Lexicon Pharmaceuticals
Sanofi

Completed

Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus on Background of Sulfonylurea Alone or With Metformin

Type 2 Diabetes Mellitus

United States, Bulgaria, Estonia, Hungary, Korea, Republic of, Poland, Romania, Slovakia, Ukraine, United Kingdom
Sanofi

Terminated

Efficacy and Safety of Sotagliflozin Versus Placebo in Chinese Patients With Type 2 Diabetes Mellitus Not Adequately Controlled by Metformin With or Without Sulfonylurea

Type 2 Diabetes Mellitus

China
Sanofi

Completed

Comparison of Pharmacodynamic Effects of Sotagliflozin and Empagliflozin in T2DM Patients With Mild to Moderate Hypertension

Diabetes Mellitus

Germany
Sanofi

Completed

Study To Determine Bioavailability of Sotagliflozin in Healthy Male and Female Subjects

Type 2 Diabetes Mellitus | Healthy Subjects

United Kingdom
Sanofi

Active, not recruiting

Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer (AMEERA-3)

Breast Cancer Metastatic

Korea, Republic of, Belgium, Taiwan, China, France, United States, Argentina, Australia, Brazil, Canada, Czechia, Greece, Israel, Italy, Japan, Latvia, Mexico, Poland, Puerto Rico, Russian Federation, Spain, Turkey, Ukraine
Sanofi

Completed

A Drug-Drug Interaction Study Between Sotagliflozin and Ramipril

Diabetes Mellitus | Healthy Subjects

Germany
Lexicon Pharmaceuticals
Sanofi

Completed

Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Participants With Type 2 Diabetes Mellitus That Are Taking Metformin Monotherapy (SOTA-GLIM)

Type 2 Diabetes Mellitus

United States, Bulgaria, Hungary, Slovakia
Sanofi

Completed

A Drug to Drug Interaction Study of Sotagliflozin With Hydrochlorothiazide

Type 2 Diabetes Mellitus

United States
Lexicon Pharmaceuticals
Sanofi

Completed

Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking Insulin Alone or With Other Oral Antidiabetic Agents (SOTA-INS)

Type 2 Diabetes Mellitus

United States, Bulgaria, Canada, Czechia, France, Hungary, Slovakia, United Kingdom
Sanofi

Recruiting

Isatuximab in Combination With Novel Agents in RRMM - Master Protocol

Plasma Cell Myeloma Refractory

France, Australia, Greece, Italy, Norway, United States, Portugal, Puerto Rico
Sanofi

Completed

Interaction Study to Evaluate the Effects of Mefenamic Acid on the Pharmacokinetics and Pharmacodynamics of Sotagliflozin in Healthy Male and Female Subjects

Diabetes Mellitus

France
Sanofi

Completed

A Drug to Drug Interaction Study of Sotagliflozin With Midazolam and Metoprolol

Type 2 Diabetes Mellitus

United States
Sanofi

Completed

Effect of Rifampicin on the Pharmacokinetics and Pharmacodynamics of Sotagliflozin

Diabetes Mellitus

France

Search clinical trials for: Amcenestrant (SAR439859)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kazakhstan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations